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Abstract
The present work reports the study of different ketoprofen:excipient formulations, in order to determine the effect of the polymer
substitution and type of diluent on the drug-release mechanism. Substituted cellulose—methylcellulose, hydroxypropylcellulose and
hydroxypropylmethylcellulose were used as polymers, while lactose monohydrate and b-cyclodextrin were tested as diluents. Distinct test
formulations were prepared, containing 57.14% of ketoprofen, 20.00% of polymer, 20.29% of diluent, and 1.71% of talc/0.86% of
magnesium stearate as lubricants. The tablets were tested for their drug content, weight variation, hardness, thickness, tensile strength,
friability, swelling and release ratio. Polymers MC25 and HPC were found not to be appropriate for the preparation of modified release
ketoprofen hydrophilic matrix tablets, while HPMC K15M and K100M showed to be advantageous. The analysis of the release profiles in the
light of distinct kinetic models (zero-order, first-order, Higuchi and Korsmeyer–Peppas) led to the conclusion that the type of polymer did
not influence the release mechanism of the drug. The mean dissolution time (MDT) was determined, the highest MDT value being obtained
for HPMC formulations. Moreover, the drug-release process was found to be slightly influenced by the type of diluent, either lactose or
b-cyclodextrin.
q 2004 Elsevier B.V. All rights reserved.
Keywords: Ketoprofen; Hydrophilic cellulose tablets; Controlled release; Matrix tablets; Cellulose polymers
1. Introduction
Ketoprofen [2-(3-benzoylphenyl)propionic acid] is a
non-steroidal anti-inflammatory drug (NSAID), widely
used in order to reduce pain, inflammation and stiffness
caused by several conditions such as osteorarthritis,
rheumatoid arthritis, ankylosing spondylitis or abdominal
cramps associated with menstruation. The mechanism of
action of ketoprofen is mainly associated to the inhibition of
the body’s ability to synthesise prostaglandins. Ketoprofen
is usually formulated and administered as a racemic mixture
of R and S enantiomers, which are equivalent on a per
weight basis. It exhibits enantiomeric selectivity, only
the S(þ )-enantiomer displaying pharmacodynamic activity
[1,2]. Conventional dosage forms of this drug, administered
orally, are rapidly and almost completely absorbed from the
gastro-intestinal tract, the peak plasma concentrations
occurring within 1–3 h [1,3]. Ketoprofen is an appropriate
model drug for formulation of controlled release dosage
forms due to its short plasma elimination half-life and poor
solubility in unionised water, which affects its biovailability
[4,5]. Therefore, in order to maintain therapeutic plasma
levels, modified release dosage forms may be beneficial,
allowing only one daily administration of the drug with
consequent improvement of patient compliance [6].
In recent years, the use of hydrophilic polymers, in
particular cellulose derivatives, has attracted considerable
attention for the development of controlled release technol-
ogy in the formulation of pharmaceutical products, due to
their ability to form gels in aqueous medium.
Previous studies developed by Williams et al. [7] led to
the conclusion that the type and level of excipient influenced
the rate and extension of drug release. Recently, Samani
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et al. [8] investigated the effect of polymer blends on release
profiles of sodium diclofenac from matrices and the results
showed that the drug release depends on the kind of
polymer, its proportion in the formulation and its viscosity
grade. Hydroxypropylmethylcellulose, is used to control
drug release from several pharmaceutical systems because
of its non-toxic nature, easy compression, swelling proper-
ties and accommodation to high levels of drug. This
cellulose derivative excipient has been widely investigated
in our laboratory [9–11]. Despite the high number of papers
on this subject, few of them discuss the drug-release
processes from both methylcellulose [12,13] and hydro-
xypropylcellulose [14,15].
The main objective of the present study is to evaluate
the effect of polymers on the kinetics of the drug release,
using distinct formulations, in order to understand how
they rule this process. This will hopefully allow the
design of more suitable cellulose matrices. The influence
of the diluent is also examined. The cellulose ether
polymers methylcellulose (MC), hydroxypropylcellulose
(HPC) and hydroxypropylmethylcellulose (HPMC), the
diluents lactose monohydrate (LAC) and b-cyclodextrin
(b-CD), and the lubricants talc and magnesium stearate
were studied.
2. Materials and methods
2.1. Materials
Drug: ketoprofen, Sigma-Aldrich Chemie, Germany.
Polymers: methylcellulose, Methocelw MC25, Fluka,
Switzerland; hydroxypropylcellulose, Klucel, USA; hydro-
xypropylmethylcellulose, Methocelw K15M and Metho-
celw K100M, Colorcon, England. Diluents: b-cyclodextrin,
Kleptosew, Roquette, Lestrem, France; lactose monohy-
drate Granulacw 200, Meggle, Wasserburg, Germany.
Lubricants: talc and magnesium stearate (analytical
grade). Indium: Aldrich, Milwaukee, USA.
2.2. Differential scanning calorimetry (DSC)
Thermal analysis were carried out using a Shimadzu
DSC-50 calorimeter, coupled to a Shimadzu TA-50
analyser. The samples were heated in sealed aluminium
pans, under a nitrogen flow (20 ml/min). About 2.5 mg of
either pure drug or pure excipient, or 5 mg of the
drug:excipient mixture was analysed, at a heating rate of
10 8C/min, from 25 to 250 8C, an empty sealed pan being
used as reference. The apparatus was calibrated with indium
(99.98%, m.p. 156.65 8C).
2.3. Preparation of the matrix tablets
The distinct formulations of the matrix tablets analysed
along this study are provided in Table 1. The tablets were
prepared containing 57.14% of drug (KETO), 20.00% of
polymer (MC25, HPC, HPMC K15M or HPMC K100M),
20.29% of diluent (LAC or b-CD), 1.71% of talc and 0.86%
of magnesium stearate as lubricants. The drug, polymer and
diluent were passed through a 100 mesh sieve
and thoroughly mixed in a plastic bag for 15 min. Talc
and magnesium stearate were sieved (500 mesh), added to
the previous mixture and blended for 5 min more. All
matrices (total mass of 350 mg) were prepared by direct
compression in an automatic hydraulic press (Speca Press,
England), using flat 10 mm diameter punches and a
compaction pressure of 624 MPa.
2.4. Assay of ketoprofen in matrix tablets
Five randomly chosen tablets of each of the formulations
tested were thinly minced in a mortar, and 17.5 mg of the
resulting powder was solubilised in phosphate buffer
(pH 7.2, USP25) [16], up to a final volume of 100 ml.
Several aliquots were then filtered and assayed spectro-
photometrically at 320 nm, in a Shimadzu UV-1603
spectrophotometer. Each measurement was carried out in
triplicate and the results averaged. A blank solution
(containing all the components except from the drug) was
Table 1
Composition of the distinct hydrophilic formulations of ketoprofen
Component Formulation (mg)
F1 F2 F3 F4 F5 F6 F7 F8
Ketoprofen 200.0 200.0 200.0 200.0 200.0 200.0 200.0 200.0
MC25 70.0 70.0 – – – – – –
HPC – – 70.0 70.0 – – – –
HPMC K15M – – – – 70.0 70.0 – –
HPMC K100M – – – – – – 70.0 70.0
Lactose 71.0 – 71.0 – 71.0 – 71.0 –
b-CD – 71.0 – 71.0 – 71.0 – 71.0
Talc 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0
Mg stearate 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0
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also prepared. No other assay method was considered
necessary since no interferences were observed at 320 nm.
2.5. Weight, hardness and thickness of tablets
A total of 20 tablets of each formulation was evaluated
for weight (analytical balance KERN 770). For each
formulation, the hardness of 10 tablets was examined
using an Erweka hardness tester TBH28.
The thickness was determined using a micrometer
(Roche, Switzerland). Ten individual tablets of each
formulation were used.
2.6. Tensile strength
The tensile strength ðTÞ was determined, for 10 matrix
tablets of each formulation, from the force required to
fracture the tablets by diametral compression, on a tablet
hardness tester (Erweka TBH28, Germany), according to
the following equation:
T ¼ 2P
pDt
ð1Þ
where P is the applied load, and D and t represent the
diameter and thickness of the tablet, respectively [17].
2.7. Friability
Twenty tablets were weighed and placed into a
friabilitor (Erweka TA20, Germany). The samples under-
went 25 rotations per minute, for 4 min, and were then
re-weighed. This process was repeated for all formulations
and the percentage friability was calculated using the
equation:
F ¼ W1 2W2
W1
£ 100 ð2Þ
where F represents the percentage weight loss, and W1
and W2 are the initial and final tablets weights,
respectively.
2.8. Swelling
Swelling studies were carried out for all formulations.
Three metallic baskets containing a matrix tablet of each
formulation were weighed, and placed in 1000 ml of
phosphate buffer (pH 7.2) at 37.0 ^ 0.5 8C. At hourly
intervals, the previously weighted baskets with the tablet
were removed, gently wiped with a tissue to remove surface
water, re-weighted and then placed back into the vessel as
quickly as possible. The mean weights were determined for
each formulation, and the degree of swelling ðSÞ was
calculated according to the relationship [18]:
S ¼ Ws 2Wd
Wd
£ 100 ð3Þ
where Wd and Ws are the dry and swollen matrix weights,
respectively, at immersion time t in the buffer. The swelling
degree was the mean value of three measurements.
2.9. Drug release analysis
Release studies were carried out according to the USP 25
paddle method [16]. The dissolution medium was phosphate
buffer (pH 7.2, 1000 ml) at 37.0 ^ 0.5 8C, and a stirring
speed of 100 rpm was used. A closed-flow in-line mutiple
vessel dissolution apparatus (Vankel VK-7000 dissolution
testing station), connected to a spectrophotometer
(Shimadzu UV-1603), was used for this purpose. Six
different tablets were tested. Progress of the release was
monitored by withdrawing filtered samples every 5 min, for
a total of 1200 min. The amount of ketoprofen present in
each sample was determined spectrophotometrically, at
l ¼ 320 nm. The corresponding drug-release profiles were
represented through plots of the cumulative percentage of
drug release (calculated from the total amount of ketoprofen
contained in each matrix) versus time.
2.9.1. Kinetic mechanism
Different mathematical models may be applied for
describing the kinetics of the drug-release process from
matrix tablets, the most suited being the one which best fits
the experimental results.
The kinetics of ketoprofen release from hydrophilic
cellulose formulations was determined by finding the best fit
of the dissolution data (drug-released fraction versus time)
to distinct models: zero-order (4), first-order (5) and Higuchi (6)
[19,20]:
Qt ¼ Q0 þ k0t ð4Þ
where Qt is the amount of drug released at time t; Q0 the
amount of drug in the solution at t ¼ 0; (usually, Q0 ¼ 0)
and k0 the zero-order release constant
Qt ¼ Q1ð12 e2k1tÞ ð5Þ
Q1 being the total amount of drug in the matrix and k1 the
first-order kinetic constant.
Qt ¼ kHt1=2 ð6Þ
kH representing the Higuchi rate constant.
Furthermore, in order to better characterise the drug-
release behaviour for the polymeric systems studied, namely
to understand the corresponding mechanism, the Kors-
meyer–Peppas (7) semi-empirical model was applied [21].
Qt=Q1 ¼ ktn ð7Þ
where Qt=Q1 is the fraction of drug released at time t; k a
constant comprising the structural and geometric character-
istics of the tablet, and n; the release exponent, is a
parameter which depends on the release mechanism and is
thus used to characterise it [22]. For the case of cylindrical
tablets [23], in particular, n # 0:45 corresponds to a Fickian
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diffusion release (case I diffusional), 0:45 , n # 0:89 to an
anomalous (non-Fickian) transport, n ¼ 0:89 to a zero-order
(case II) release kinetics, and n . 0:89 to a super Case II
transport.
A direct fitting of the drug-release data to the non-linear
equations described above is usually avoided by performing
a linear transformation of the data, followed by regression
analysis. Nevertheless, this method may not be mathemat-
ically accurate, as it uses transformed values (logarithms)
instead of the original data [24]. Therefore, a direct
non-linear fitting of the experimental results was carried
out in the present work, for each of the mathematical
models considered (through minimisation of the sum of
the squared residuals). Only the points within the interval
0:1 , Qt=Q1 , 0:7 were used.
2.9.2. Mean dissolution time
To further characterise the drug-release process, the
mean dissolution time (MDT) was calculated according to
the following equation:
MDT ¼
Xn
j¼1 t^jD QjXn
j¼1 DQj
ð8Þ
where j is the sample number, n the number of time
increments considered, t^j the time at midpoint between tj
and tj21; and DQj the additional amount of drug dissolved in
the period of time tj and tj21:
2.10. Statistics
All results were expressed as mean values ^ standard
deviation (SD). In order to assess the statistical significance
between the data, a single-factor analysis of variance
(ANOVA) was carried out, at a 5% significance level.
3. Results and discussion
3.1. Differential scanning calorimetry (DSC)
In order to investigate the possible interactions between
ketoprofen and distinct polymers and/or diluents,
differential scanning calorimetry studies were carried out.
The 1:1 weight ratio was chosen because it maximises the
likelihood of observing any interactions. The thermal curve
of ketoprofen (Fig. 1) displayed a single sharp endothermic
peak at 96 8C, corresponding to the melting point of the drug
[25]. A large shallow broad endothermic effect, over the
temperature range 60–140 8C, was observed for the
polymers MC25, HPC, HPMC K15M and HPMC K100M
(Fig. 1), upon evaporation of adsorbed water. Actually, it
was reported that the thermal analysis of cellulose exhibits
an endothermic effect above 100 8C [26–28]. The DSC
trace of b-CD showed a broad endothermic effect,
which attained a maximum around 120 8C, corresponding
to a dehydration process [29]. Lactose thermogram, in turn,
displayed two sharp endothermic peaks, at both 147 and
219 8C.
Regarding the (1:1) ketoprofen:excipient mixtures stu-
died, the corresponding thermograms (Fig. 2) were found
not to be a simple superposition of the ones obtained for
each component separately. In fact, except in the case of
MC25 (Fig. 2 (A:B)), there is a clear downward shift of the
dehydration excipient signal relative to the free polymer,
probably due to the presence of a non-negligible drug:exci-
pient interaction. Actually, this could be responsible for
Fig. 1. DSC curves for ketoprofen and the different excipients studied.
KETO (A), MC25 (B), HPC (C), HPMC K15M (D), HPMC K100M (E),
b-CD (F) and lactose (G).
Fig. 2. DSC curves for ketoprofen and 1:1 (w/w) mixtures of ketoprofen
with: MC25 (A:B), HPC (A:C), HPMC K15M (A:D), HPMC K100M
(A:E), b-CD (A:F) and lactose (A:G).
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a loosening of the water–polymer binding strength, due to a
certain competition from the drug ionisable groups (e.g.
carboxylates).
The ketoprofen:b-CD mixture exhibited the
characteristic shift of the drug melting point to lower
temperatures—DT ca. 6 8C—which is indicative of a certain
loss of crystallinity (Fig. 2). The signal corresponding to the
dehydration process of b-CD, in turn, is increased by ca.
50 8C. These observations reflect the existence of strong
solid–solid interactions between the two components, in
this formulation. Once no other thermal event occurred,
these interactions do not necessarily indicate an incompat-
ibility [30].
On the other hand, when lactose was combined to the
drug—in a (1:1) (w:w) ratio—a downward shift of the
excipient melting peak was detected, coupled to a
broadening effect (Fig. 2), in accordance with findings
previously reported by other authors [30]. Even though 1:1
is not the anticipated ratio for the final dosage form, as no
extra thermal events were found in the corresponding
thermogram and the ketoprofen signal appears unaffected,
the results now obtained allow us to conclude that no
incompatibility is present between ketoprofen and lactose.
3.2. Physical characteristics of ketoprofen hydrophilic
cellulose matrices
As summarised in Table 2, the evaluation of the prepared
hydrophilic matrix tablets containing ketoprofen showed
that the drug content of all formulations ranged from 98.24
to 100.75%, indicating a uniform amount of drug in the
formulations. The physical characteristics of these tablets
provided good weight uniformity, as indicated by the very
low relative standard deviation obtained (RSD , 1% in all
formulations). Each of the polymers used, with different
excipients, yielded matrix tablets with a hardness value
from 82.10 to 220.90 N. It was also observed that a variation
in the tablet hardness was accompanied by an obvious
change in tablet tensile strength, evidencing a variation of
tensile strength from 1.440 to 3.995 MPa. The tablets also
passed the friability test ðF , 1%Þ; showing that all
formulations are within the USP25 limits [16].
3.3. Swelling studies
Swelling studies were carried out, in order to investigate
whether the extent of swelling varied for the different
formulations. When a matrix comes into contact with an
aqueous solution, wetting occurs, first at the surface and
then progressing into the matrix through microscopic pores.
The nature of the polymer plays an important role in this
swelling process of the matrix tablets. The presence of water
in the polymer causes a certain amount of stress, resulting in
hydration of the polymer, which starts to swell yielding a
gelatinous viscous layer [31–36].
The results obtained from these swelling studies are
represented in Figs. 3 and 4. From analysis of this data,
it was possible to conclude that for the MC25 and
HPC-containing matrix tablets the amount of aqueous
uptake absorbed (and consequently the degree of swelling)
was lower than for formulations containing HPMC K15M or
HPMC K100M. The MC25 matrices, in particular,
displayed a quite different behaviour as compared to the
other polymers tested: the absence of hydroxypropoxyl
groups in its structure is responsible for a lower
hydrophilicity [37] and thus for a lower water uptake;
moreover, at about 1 h after the start of the experiment, a
gradual disintegration process was clearly evident from the
significative decrease in the water uptake.
For the HPC-containing formulations, on the other hand,
a lower hydration was observed, even for long water
exposure periods. Roy et al. [38] calculated the swelling
kinetic constant ðk ¼ 2:47Þ for this polymer, and suggested
that its low value could be explained by the absence of a
burst effect during swelling. However, the swelling process
was found to vary considerably from the isolated polymer to
the formulations tested along the present work, as the
maximum plateau value is attained after 6 h of water
exposure for the former and after only 1 h for the latter.
The amount of swelling obtained for the formulations
containing both HPMC K15M and HPMC K100M
evidenced a high hydration degree already after the first
hour of water exposure—around double the one measured
for the HPC system—this water content being constant
from then on. This large degree of swelling is attributed to
Table 2
Physical characterisation of ketoprofen hydrophilic matrix tablets
Formulation Weight
(mg)a n ¼ 20
Weight RSD
(%)
Hardness
(N) n ¼ 10
Thickness
(mm) n ¼ 10
Tensile strength
(MPa) n ¼ 10
Friability
(%) n ¼ 20
Drug content
(mg) n ¼ 3
F1 348.95 ^ 1.02 0.29 220.96 ^ 2.69 3.52 ^ 0.03 3.995 ^ 0.051 0.18 196.48 ^ 0.75
F2 349.51 ^ 1.37 0.39 213.86 ^ 1.87 3.50 ^ 0.03 3.889 ^ 0.052 0.77 201.06 ^ 3.04
F3 348.32 ^ 0.98 0.28 88.32 ^ 1.06 3.60 ^ 0.03 1.562 ^ 0.028 0.71 197.59 ^ 1.22
F4 349.06 ^ 1.43 0.41 82.12 ^ 1.60 3.63 ^ 0.06 1.440 ^ 0.025 0.80 201.47 ^ 0.42
F5 349.21 ^ 0.80 0.23 205.26 ^ 2.30 3.56 ^ 0.02 3.675 ^ 0.040 0.65 200.44 ^ 1.30
F6 349.12 ^ 0.62 0.18 200.26 ^ 1.48 3.55 ^ 0.02 3.595 ^ 0.034 0.85 197.73 ^ 0.50
F7 348.57 ^ 0.67 0.19 210.16 ^ 2.13 3.55 ^ 0.02 3.768 ^ 0.050 0.27 199.00 ^ 2.42
F8 349.16 ^ 1.46 0.42 201.16 ^ 3.21 3.58 ^ 0.04 3.581 ^ 0.055 0.67 198.51 ^ 0.30
a n is the number of measurements.
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the presence of the highly hydrophilic hydroxypropoxyl
groups in these polymers.
Cheong et al. [39] reported studies on polymer
viscosity—which influences the drug-release process from
a matrix system—having concluded that the high viscosity
grades of HPMC (e.g. HPMC K100M) are explained by
the presence of substituent groups which, by interacting
with water, lead to an increase of swelling.
3.4. Drug release analysis
Figs. 5 and 6 comprise the release profiles of ketoprofen
from the distinct types of hydrophilic matrices studied. The
MC25-containing tablet disintegrated, leading to a rapid
release of the drug (in about 1 h). This is an indication that
Fig. 3. Graphical representation of the water uptake versus time for several
lactose-containing formulations (Table 1) of ketoprofen.
Fig. 4. Graphical representation of the water uptake versus time for several
b-cyclodextrin-containing formulations (Table 1) of ketoprofen.
Fig. 5. Drug-release profiles for ketoprofen from lactose-containing
formulations (Table 1).
Fig. 6. Drug-release profiles for ketoprofen from b-cyclodextrin-containing
formulations (Table 1).
Table 3
Calculated MDT values
Formulation MDT (h)
F3 1.58 ^ 0.02
F4 1.80 ^ 0.02
F5 7.62 ^ 0.07
F6 8.63 ^ 0.18
F7 9.11 ^ 0.04
F8 9.58 ^ 0.07
Mean ^ SD (six measurements).
Fig. 7. Maximal MDT values (Table 3).
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dissolution from MC25 formulations cannot be controlled.
In turn, ketoprofen release from HPC was not as immediate.
Different authors reported identical data [40] for other
drugs. Regarding the formulations containing HPMC, the
results showed that, after 20 h, 70–80% of the drug was
released from F5 and F6 matrices (K15M), and 60–65%
from formulations F7 and F8 (K100M).
It was verified that the presence of cyclodextrins into
polymeric drug delivery systems can also influence the
drug-release mechanism by Bibby et al. [41]. In the present
study, b-CD was tested as a diluent in the ketoprofen matrix
tablets, and the results evidenced that release profiles of
these formulations were only slightly slower than those
containing lactose. This is probably due to an inclusion
process of the ketoprofen molecule in b-cyclodextrin, which
may be considered energetically favoured when compared
to inclusion of similar drugs, namely ibuprofen [42,43]. The
MDT-calculated values for all the matrices investigated
(Table 3, Fig. 7) corroborate these findings, once this
parameter reflects the drug-release process—larger values
indicating higher drug retarding ability of the formulation.
In fact, it was verified that all formulations containing b-CD
as a diluent yielded higher MDT values.
On the other hand, the polymer type (e.g. its viscosity)
was also found to influence MDT. Thus, larger values (by
ca. 7–8 h) were determined for HPMC (either K15M or
K100M) as compared to HPC, the highest values having
been obtained for K100M (Fig. 7).
3.4.1. Kinetic mechanism
The drug release mechanism from swellable matrices is
complex and not yet completely understood. Although some
processes may be classified as either purely diffusional or
purely erosion controlled, many others can only be
interpreted as being governed by both. The analysis of
experimental data in the light of the Korsmeyer–Peppas
equation (7), as well as the interpretation of the
corresponding release exponent values ðnÞ; leads to a
better understanding of the balance between these
mechanisms.
This kind of analysis was performed for all the
formulations under study, with the exception of F1 and F2
once, in these cases, more than 70% of the drug was
already released during the first hour of the experiment
(Figs. 5 and 6).
For F3 and F4 formulations, n was determined to be
equal to 0.816 and 0.842, respectively (Table 4).
Notwithstanding these values pointing to an anomalous
(non-Fickian) diffusional mechanism, both Higuchi’s model
(Fickian) and first-order kinetics yielded similarly good
quality adjustments. High values of KKP found for these
formulations (Table 4), in turn, suggest the possibility of
occurrence of a burst effect for the HPC-containing
matrices. Moreover, it is also known that HPC may yield
mesophases [44], which certainly influence the kinetic
behaviour of this polymer.T
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For HPMC-containing formulations, F5 – F8, the
diffusional exponent value ðnÞ ranged from 0.621 to 0.671
(Table 4), indicating that the release mechanism of
ketoprofen from these matrices is an anomalous (non-
Fickian) transport, which suggests that both diffusion of the
drug in the hydrated matrix and its own erosion modulate
drug release. For these systems, the first-order kinetic
model yielded remarkably good adjustment ðR2 . 0:999Þ:
These results are in agreement with those reported by
Rodriguez et al. [45].
4. Conclusions
From the DSC thermograms alone, it is possible to
conclude that the selected excipients are likely to be suitable
for the preparation of tablet formulations, since no
significative incompatibilities were detected. In fact, even
when drug:excipient interactions were detected, they were
not found to affect the drug bioavailability. The swelling
experiments, in turn, showed that the water uptake increases
with the polymer viscosity, which is a rather important
factor to consider when preparing hydrophilic matrix
tablets. According to the release studies, polymers MC25
and HPC are not appropriate for the preparation of modified
ketoprofen hydrophilic matrix tablets, in the conditions
under study, while HPMC K15M and K100M may be
advantageous. On the other hand, despite no substantial
differences were found when lactose or b-CD was used as
diluents, it must be emphasised that for b-CD a slight
decrease on the dissolution of the tablets was observed,
probably due to the occurrence of an inclusion process
between the ketoprofen and the cyclodextrin.
The release mechanism of ketoprofen from each
formulation tested was evaluated in the light of zero-
order, first-order, Higuchi’s and Korsmeyer–Peppas kinetic
models. Non-Fickian (anomalous) transport was observed
for all cellulose ethers. Neither the effect of cellulose
substitution nor the type of diluent was determined to have a
significant impact on the release mechanism of ketoprofen
from the hydrophilic matrix tablets investigated.
The present results provide useful information on the
type of polymers and additives that should be employed on
the formulation of hydrophilic matrix tablets, namely of
those containing ketoprofen or similar drugs.
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